Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

Tirzepatide was associated with significant reductions in weight primarily due to fat mass loss while preserving lean mass in obesity.

Despite promising adherence and persistence data, tirzepatide dose escalation was slower in the real-world than clinical trials in patients with obesity without T2D. Tirzepatide dose escalation is ...

A recent analysis of the SURPASS-3 trial unravels the impact of treatment with the drug tirzepatide on muscle volume and fat infiltration in individuals with type 2 diabetes. Published in The ...

In this case, the holding changes SCHD made in its reconstitution turned out to be bad decisions in my view. As an example, the chart below compares the total returns from SCHD to the overall ...

The change in ranking means cheap games looking to make rapid sales will no longer be prioritised at the top of the charts, meaning studios will be disincentivised to game the charts with cheap ...

The Conservatives and Labour have lost their historical grip on local elections in England under the challenge from Reform UK, the Liberal Democrats and Greens. Fragmentation of voters' choices is ...

Two days after its wide release, “Death County, Pa.” has risen to the top spot of Apple’s ranking for top ‘Podcast Series.’ The six-part series is based on a years-long investigation of ...

In Siegel v.Cantor Fitzgerald, C.A. No. 2024-0146-LWW (Del. Ch. April 10, 2025), the Delaware Court of Chancery rejected the plaintiff’s attempt to distinguish Brookfield in his dilution claim ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

Here below you have a complete description of its most interesting features and benefits so you can make the most of it. The majority of other information websites display prices of a single ...